Empagliflozin

Introduction Overview

Generic Name

empagliflozin

Brand Name

Jardiance

Dosage Form

oral tablet (10 mg; 25 mg)

Drug Class

SGLT-2 inhibitors

Pharmacokinetics

Absorption: Empagliflozin is rapidly absorbed following oral administration, with peak plasma concentrations typically achieved within 1.5 to 2.5 hours. The absolute bioavailability of empagliflozin is approximately 78%, demonstrating efficient gastrointestinal uptake. Food intake does not significantly affect the pharmacokinetics of empagliflozin, allowing administration with or without food. The absorption process is consistent and reliable across patient populations, including those with type 2 diabetes.

Distribution: After absorption, empagliflozin is extensively distributed into the body tissues. It exhibits a volume of distribution of approximately 73 liters, indicating moderate tissue uptake beyond the vascular compartment. Empagliflozin is approximately 86.2% bound to plasma proteins, primarily albumin, which influences its distribution and pharmacodynamics. The drug readily reaches the renal proximal tubules, the primary site of action, but the ability to cross the blood-brain barrier is limited, minimizing central nervous system exposure.

Metabolism: Empagliflozin undergoes minimal metabolism, predominantly via glucuronidation by UDP-glucuronosyltransferase (UGT) enzymes, mainly UGT2B7, UGT1A3, UGT1A8, and UGT1A9. Oxidative metabolism via cytochrome P450 enzymes is negligible, reducing the risk of significant drug interactions through this pathway. Because metabolism is not mediated by cytochrome P450 isoenzymes, empagliflozin exhibits a low potential for interactions affecting CYP substrates.

Elimination: The elimination of empagliflozin occurs through renal and fecal pathways, with approximately 54% excreted in urine mainly as unchanged drug or metabolites and 41% recovered in feces. The terminal elimination half-life ranges between 12.4 to 18.8 hours, supporting once-daily dosing. Clearance is reduced in patients with renal impairment, necessitating dosing adjustments or contraindications in severe kidney disease or dialysis. Empagliflozin is not dialyzable. Overall, its elimination kinetics support steady-state plasma concentrations within 4 to 6 days.

Dosage Forms

Available Dosage Forms: Empagliflozin is commercially available as oral tablets in strengths of 10 mg and 25 mg. These tablets are film-coated and designed for once-daily oral administration. The formulation allows for convenient dosing with or without food.

Dosages for Adults and Adolescents: The typical starting dosage is 10 mg once daily. In patients requiring greater glycemic control and tolerating therapy well, the dose may be increased to 25 mg once daily. Empagliflozin is approved for use in adults and in children aged 10 years and older with type 2 diabetes. Dosage adjustments are not usually required based on age alone but are dependent on renal function.

Specific Patient Populations: Empagliflozin dosing should be adjusted or avoided in patients with renal impairment. It is contraindicated in patients with severe kidney disease or those on dialysis. Use during pregnancy, particularly in the second and third trimesters, is not recommended due to potential fetal risks. The drug is also contraindicated during breastfeeding. Special caution is advised in elderly patients (≥65 years), who may have altered pharmacokinetics and increased susceptibility to side effects such as dehydration and hypotension. No specific pediatric dosing adjustments beyond approved age groups are established.

Mechanism Of Action

Empagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor that acts primarily in the proximal renal tubules to reduce glucose reabsorption. By inhibiting SGLT2, which is responsible for approximately 90% of renal glucose reabsorption, empagliflozin promotes the urinary excretion of glucose (glucosuria), thereby decreasing plasma glucose concentrations independent of insulin secretion or action.

At the molecular level, empagliflozin binds specifically to the SGLT2 transporter with high affinity, competitively inhibiting the co-transport of sodium and glucose into renal tubular cells. This reduces the renal threshold for glucose, resulting in increased glucose elimination in urine. The glucose-lowering effect also contributes to improved insulin sensitivity and beta-cell function indirectly due to decreased glucotoxicity.

Beyond glycemic control, empagliflozin exerts beneficial cardiovascular and renal effects. The natriuretic effect via decreased sodium reabsorption contributes to reductions in blood pressure and plasma volume, which can alleviate cardiac workload and potentially reduce heart failure risk. Empagliflozin also modulates renal hemodynamics by restoring tubuloglomerular feedback, thereby reducing intraglomerular pressure and slowing progression of diabetic kidney disease.

Clinical trials have demonstrated that empagliflozin reduces cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease. These benefits are likely multifactorial and include metabolic, hemodynamic, and anti-inflammatory pathways enhanced by its mechanism of SGLT2 inhibition. Compared to other glucose-lowering agents such as DPP-4 inhibitors or sulfonylureas, empagliflozin’s insulin-independent action and cardiovascular benefits represent significant advantages supported by extensive research data.

Pharmacological Actions

Selective inhibition of sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubule.
Induction of glucosuria leading to reduced plasma glucose concentrations.
Reduction of renal glucose reabsorption threshold.
Natriuretic effect resulting in decreased sodium and water reabsorption.
Improvement of glycemic control independent of insulin secretion.
Reduction in body weight through loss of calories via urinary glucose excretion.
Lowering of systolic and diastolic blood pressure via osmotic diuresis and natriuresis.
Cardioprotective effects including decreased risk of cardiovascular death in type 2 diabetes with established heart disease.
Renoprotective actions via modulation of intraglomerular pressure and preservation of kidney function.
Improvement of beta-cell function secondary to decreased glucotoxicity.
Reduction in hospitalization rates for heart failure due to improved cardiac hemodynamics.
Minimal involvement with cytochrome P450 metabolism reducing drug interaction potential.
Enhancement of metabolic parameters including reduced HbA1c and fasting plasma glucose.
Potential anti-inflammatory effects contributing to cardiovascular and renal benefits.
Glucose lowering even in patients with reduced insulin sensitivity or beta-cell function.

Therapeutic Or Clinical Uses

Treatment of type 2 diabetes mellitus to improve glycemic control in adults and children aged 10 years and older.
Reduction of risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Decreasing the risk of hospitalization for heart failure in patients with type 2 diabetes.
Treatment to lower risk of cardiovascular events such as heart attack and stroke in type 2 diabetes patients with cardiovascular disease.
Adjunctive therapy combined with diet and exercise for glycemic management.
Reduction of risk of mortality or hospitalization for heart failure in adults with heart failure with reduced ejection fraction, even without diabetes.
Potential reduction in progression of diabetic kidney disease due to nephroprotective effects.
Management of hyperglycemia in patients inadequately controlled with other antidiabetic agents.
Use in patients where weight loss and blood pressure reduction are preferred therapeutic effects.
Alternative oral treatment in patients intolerant to other antidiabetic agents like metformin or sulfonylureas.
Improvement of metabolic syndrome components associated with type 2 diabetes.
Utility in patients with cardiovascular comorbidity needing combined treatment benefits.
Part of combination therapy regimens including insulin, metformin, or other oral antidiabetics.
Reduction of glucotoxicity improving long-term pancreatic beta-cell function.
Adjunctive treatment to potentially reduce insulin doses in insulin-dependent patients.

Side Or Adverse Effects

Genital mycotic infections including vulvovaginal candidiasis and balanitis due to glycosuria.
Urinary tract infections and cystitis with symptoms such as dysuria and frequency.
Signs of serious genital infections with redness, swelling, pain, or discharge requiring urgent medical evaluation.
Hypoglycemia risk, especially when used concomitantly with insulin or insulin secretagogues.
Dehydration and volume depletion manifesting as dizziness, light-headedness, or syncope.
Ketoacidosis (euglycemic diabetic ketoacidosis), characterized by nausea, vomiting, abdominal pain, and respiratory difficulty.
Increased urination due to osmotic diuresis which may lead to electrolyte imbalances.
Possible increases in LDL cholesterol levels.
Risk of acute kidney injury particularly in susceptible patients with volume depletion or renal impairment.
Hypotension due to decreased plasma volume and blood pressure lowering effects.
Potential allergic reactions including rash, itching, or anaphylaxis in rare cases.
Rare occurrences of bladder infections with hematuria or pelvic pain.
Gastrointestinal symptoms such as nausea or abdominal discomfort in some patients.
Elevations in hematocrit reflecting hemoconcentration.
Possible modest weight loss as an effect rather than an adverse event.

Precautions

Evaluate renal function before initiating therapy and periodically thereafter; avoid in severe renal impairment or dialysis.
Monitor for signs and symptoms of ketoacidosis even if blood glucose levels are normal.
Use cautiously in elderly patients due to increased risk of dehydration, hypotension, and renal impairment.
Assess for history of urinary tract or genital infections; monitor closely during treatment.
Educate patients about proper genital hygiene to reduce risk of fungal infections.
Advise patients to maintain adequate hydration, especially during illness or conditions that predispose to volume depletion.
Adjust concomitant antihypertensive and diuretic therapies to avoid excessive blood pressure reductions.
Caution in patients with low blood pressure, or history of orthostatic hypotension.
Avoid use during pregnancy, particularly in the second and third trimesters due to potential harm to fetal renal development.
Not recommended during breastfeeding as safety data are insufficient.
Patients should inform healthcare providers prior to surgery or planned medical procedures to manage fluid and medication adjustments.
Routine monitoring for electrolyte disturbances is advised in patients at risk.
Be vigilant for signs of hypersensitivity reactions and discontinue if suspected.
Counsel patients on signs of hypoglycemia and management strategies when used with insulin or sulfonylureas.
Advise avoidance or cautious use of alcohol which may potentiate hypoglycemia and dehydration.

Warnings

Risk of serious genital infections including Fournier’s gangrene requiring immediate medical attention.
Potential for life-threatening diabetic ketoacidosis even with near-normal blood glucose levels.
Possible volume depletion leading to symptomatic hypotension, dizziness, and syncope.
Not recommended for use in patients with type 1 diabetes mellitus due to increased risk of ketoacidosis.
Avoid use in patients with severe renal impairment, end-stage renal disease, or on dialysis.
Use with caution in patients who are elderly or have conditions predisposing to dehydration.
May cause acute kidney injury, especially in patients with volume depletion or concomitant nephrotoxic drugs.
Potential elevation of LDL cholesterol requiring monitoring.
Risk of hypoglycemia increased when combined with insulin or insulin secretagogues.
Avoid abrupt discontinuation to prevent loss of glycemic control and cardiovascular benefits.
Use caution when performing tasks requiring mental alertness until response to medication is known.
Potential interference with certain laboratory tests; inform healthcare providers of therapy.
Warning for rare allergic reactions including anaphylaxis.
Patients should report symptoms like persistent stomach pain, nausea, vomiting, fatigue, or difficulty breathing promptly.
Pregnancy category contraindication during second and third trimesters.

Contraindication

Known hypersensitivity or allergy to empagliflozin or any component of the formulation.
Severe renal impairment defined as eGFR less than 30 mL/min/1.73 m².
End-stage renal disease and patients on dialysis.
Type 1 diabetes mellitus due to risk of diabetic ketoacidosis.
Pregnancy during the second and third trimesters.
Breastfeeding due to lack of safety data and potential risks.
History of hypersensitivity reactions to SGLT2 inhibitors.
Patients with active bladder cancer (due to class concerns, use with caution).
Concomitant use with other SGLT2 inhibitors (to avoid additive adverse effects).
Severe hepatic impairment without clear clinical benefit-risk assessment.
Patients with recurrent severe urinary tract infections or untreated genitourinary infections.
Known conditions predisposing to ketoacidosis not manageable by this treatment.
Situations where volume depletion cannot be corrected prior to treatment.
Known hypersensitivity to excipients of the tablet formulation causing allergic reactions.
Concomitant use with drugs known to increase risk of hypovolemia or hypotension without close monitoring.

Drug Interactions

Insulin and insulin secretagogues (e.g., sulfonylureas) increase risk of hypoglycemia when used with empagliflozin.
Diuretics ('water pills') may potentiate volume depletion and hypotension when combined with empagliflozin.
Other antihypertensive agents may increase risk of symptomatic hypotension when co-administered.
Lithium levels may be affected due to changes in renal clearance; monitoring recommended.
Potential pharmacodynamic interaction with NSAIDs leading to renal function impairment.
Caution advised with nephrotoxic agents (e.g., aminoglycosides, radiocontrast agents).
Drugs extensively metabolized by UGT enzymes are unlikely to be significantly affected due to minimal CYP450 involvement of empagliflozin.
Potential interaction with alcohol increasing risk of hypoglycemia and dehydration.
Concomitant use with other SGLT2 inhibitors is not recommended due to additive risks.
No significant interaction with metformin, but combined use requires monitoring of glycemic control.
Effects on diuretic efficacy and electrolytes when used with potassium-sparing agents should be monitored.
Co-administration with RAAS inhibitors may increase risk of volume depletion.
No clinically meaningful interaction observed with commonly co-administered antidiabetics like DPP-4 inhibitors, GLP-1 receptor agonists.
Use caution with medications that can cause hypoglycemia or hypotension, requiring dose adjustments.
Empagliflozin does not inhibit or induce cytochrome P450 enzymes to a clinically significant extent, limiting metabolic interactions.

Preparations Of The Drug

Empagliflozin is formulated as film-coated oral tablets.
Available in strengths of 10 mg and 25 mg for once-daily administration.
Tablets are designed for oral use and may be taken with or without food.
Packaged typically in blister packs or bottles ensuring moisture protection.
Stable at room temperature, protected from excessive heat and moisture.
No injectable or intravenous formulations currently available.
No extended-release or modified-release formulations marketed to date.
Prescribed solely based on indication, renal function, and tolerability.
Supplied with medication guides detailing administration, storage, and side effects.
Available commercially under the brand name Jardiance and in certain generic markets.
Dosage form selected for ease of adherence in chronic type 2 diabetes therapy.
Not combined with other agents in fixed-dose formulations.
Available through prescription with appropriate medical supervision.
Storage recommendations include keeping tablets in original container away from children.
Packaging designed to minimize degradation and maintain drug stability.